This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Johns Hopkins University. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Sara Sanders: Innovator in RNA Polymerase Inhibition
Introduction
Sara Sanders is a prominent inventor based in St. Louis, MO (US). She has made significant contributions to the field of molecular biology, particularly in the area of RNA polymerase inhibition. Her work has implications for cancer treatment and understanding the mechanisms of ribosomal RNA transcription.
Latest Patents
Sara Sanders holds a patent for "Compounds which inhibit RNA polymerase, compositions including such compounds, and their use." This invention focuses on RNA polymerase I (Pol I), which is crucial for the transcription of the 47S ribosomal RNA precursor. The patent describes a series of pyridoquinazolinecarboxamides synthesized as inhibitors of Pol I and activators of the degradation of RPA194, the large catalytic subunit protein of Pol I. The invention identifies bioactive compounds that effectively cause RPA194 degradation, with potential applications in treating cancer and other diseases related to Pol I.
Career Highlights
Sara Sanders is affiliated with The Johns Hopkins University, where she conducts her research. Her innovative work has led to advancements in understanding the role of Pol I in human cancers. She has successfully synthesized compounds that target this polymerase, contributing to the development of new therapeutic strategies.
Collaborations
Sara has collaborated with notable researchers, including Marikki Laiho and Laureen Colis. These partnerships have enhanced her research efforts and expanded the impact of her findings in the scientific community.
Conclusion
Sara Sanders is a trailblazer in the field of RNA polymerase research, with a focus on developing compounds that inhibit Pol I. Her contributions are paving the way for new cancer treatments and advancing our understanding of ribosomal RNA transcription.